EP1516049A4 - Zusammensetzungen und verfahren für die therapie und diagnose von lungenkrebs - Google Patents

Zusammensetzungen und verfahren für die therapie und diagnose von lungenkrebs

Info

Publication number
EP1516049A4
EP1516049A4 EP02739247A EP02739247A EP1516049A4 EP 1516049 A4 EP1516049 A4 EP 1516049A4 EP 02739247 A EP02739247 A EP 02739247A EP 02739247 A EP02739247 A EP 02739247A EP 1516049 A4 EP1516049 A4 EP 1516049A4
Authority
EP
European Patent Office
Prior art keywords
diagnosis
compositions
treatment
methods
lung cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02739247A
Other languages
English (en)
French (fr)
Other versions
EP1516049A2 (de
Inventor
Michael J Lodes
Tongtong Wang
Liqun Fan
Paul A Algate
Patricia D Mcneill
Robert A Henderson
Raodoh Moahamath
Heather Secrist
Darin R Benson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/854,133 external-priority patent/US6759508B2/en
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of EP1516049A2 publication Critical patent/EP1516049A2/de
Publication of EP1516049A4 publication Critical patent/EP1516049A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP02739247A 2001-05-11 2002-05-10 Zusammensetzungen und verfahren für die therapie und diagnose von lungenkrebs Withdrawn EP1516049A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US854133 2001-05-11
US09/854,133 US6759508B2 (en) 2000-09-01 2001-05-11 Compositions and methods for the therapy and diagnosis of lung cancer
PCT/US2002/014975 WO2002092001A2 (en) 2001-05-11 2002-05-10 Compositions and methods for the therapy and diagnosis of lung cancer

Publications (2)

Publication Number Publication Date
EP1516049A2 EP1516049A2 (de) 2005-03-23
EP1516049A4 true EP1516049A4 (de) 2006-01-11

Family

ID=25317820

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02739247A Withdrawn EP1516049A4 (de) 2001-05-11 2002-05-10 Zusammensetzungen und verfahren für die therapie und diagnose von lungenkrebs

Country Status (3)

Country Link
EP (1) EP1516049A4 (de)
AU (1) AU2002311909A1 (de)
WO (1) WO2002092001A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
US7226791B2 (en) * 2003-06-02 2007-06-05 Bristol-Myers Squibb Company Polynucleotides encoding novel guanylate binding proteins (GBP's)
PT2322221E (pt) 2008-08-05 2014-09-19 Toray Industries Composição farmacêutica para tratamento e prevenção de cancro
BRPI0911925B8 (pt) * 2008-08-05 2024-02-06 Toray Industries Método para detectar um câncer
PL2532364T3 (pl) 2010-02-04 2016-11-30 Kompozycja farmaceutyczna zawierająca przeciwciała anty CAPRIN-1 do leczenia i/lub zapobiegania nowotworowi
KR101805520B1 (ko) 2010-02-04 2017-12-07 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
CA2788716C (en) 2010-02-04 2019-06-18 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
ES2583627T3 (es) 2010-02-04 2016-09-21 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la prevención del cáncer
US8709418B2 (en) 2010-02-04 2014-04-29 Toray Industries, Inc. Pharmaceutical composition for treating CAPRIN-1 expressing cancer
BR112012018943A8 (pt) 2010-02-04 2017-12-19 Toray Industries medicamento e método para o tratamento e/ou prevenção de um câncer
WO2013018886A1 (ja) 2011-08-04 2013-02-07 東レ株式会社 膵臓癌の治療及び／又は予防用医薬組成物
HUE030137T2 (en) 2011-08-04 2017-04-28 Toray Industries Pharmaceutical preparation for the treatment and / or prevention of cancer
ES2634249T3 (es) 2011-08-04 2017-09-27 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la profilaxis del cáncer
PT2741085T (pt) 2011-08-04 2017-06-30 Toray Industries Método para a deteção de cancro prancreático
RU2595400C2 (ru) 2011-08-04 2016-08-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
RU2624049C2 (ru) 2011-08-04 2017-06-30 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и профилактики злокачественной опухоли
MX348578B (es) 2011-08-04 2017-06-20 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
EP2818483B1 (de) 2012-02-21 2017-08-02 Toray Industries, Inc. Medizinische zusammensetzung zur behandlung oder prävention von krebs
MX360211B (es) 2012-02-21 2018-10-24 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
CA2864999C (en) 2012-02-21 2020-06-30 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
US9273130B2 (en) 2012-02-21 2016-03-01 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
CN104220095B (zh) 2012-03-30 2016-09-07 东丽株式会社 肝癌的治疗和/或预防用药物组合物
CA2869123C (en) 2012-03-30 2021-03-16 Toray Industries, Inc. Pharmaceutical composition comprising anti-caprin-1 antibodies for the treatment of gallbladder cancer
PL2876447T3 (pl) 2012-07-19 2020-05-18 Toray Industries, Inc. Sposób wykrywania nowotworu
EP2876446B1 (de) 2012-07-19 2018-12-26 Toray Industries, Inc. Verfahren für den nachweis von krebs
EP3031826B1 (de) 2013-08-09 2018-10-10 Toray Industries, Inc. Pharmazeutische zusammensetzung zur behandlung und/oder prävention von krebs

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000828A2 (en) * 1999-06-30 2001-01-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2001072295A2 (en) * 2000-03-29 2001-10-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2001096390A2 (en) * 2000-06-09 2001-12-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968770A (en) * 1995-02-10 1999-10-19 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease using rchd523 as a target

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000828A2 (en) * 1999-06-30 2001-01-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2001072295A2 (en) * 2000-03-29 2001-10-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2001096390A2 (en) * 2000-06-09 2001-12-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL 2 May 2001 (2001-05-02), "Homo sapiens cystine/glutamate transporter xCT mRNA", XP002337270, retrieved from EBI Database accession no. AF252872 *
DATABASE EMBL 5 August 1999 (1999-08-05), "Seq ID no: 3414", XP002337271, retrieved from EBI Database accession no. AAZ15945 *
DATABASE EMBL XP002337272, retrieved from EBI Database accession no. AAZ12811 *

Also Published As

Publication number Publication date
WO2002092001A3 (en) 2005-01-13
EP1516049A2 (de) 2005-03-23
AU2002311909A1 (en) 2002-11-25
WO2002092001A2 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
EP1516049A4 (de) Zusammensetzungen und verfahren für die therapie und diagnose von lungenkrebs
EP1692318A4 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von lungenkrebs
EP1515982A4 (de) Zusammensetzungen und verfahren zur therapie und diagnose von prostatakrebs
EP1639090A4 (de) Zusammensetzungen und verfahren zur behandlung und diagnose von krebs
EP1583504A4 (de) Verfahren und zusammensetzungen für diagnose, prognose und behandlung von krebs
EP1589933A4 (de) Zusammensetzungen und verfahren für dietumor-diagnose und behandlung
NO20016427D0 (no) Blandinger og fremgangsmåter for behandling av diagnose av lungekreft
EP1578371A4 (de) Zusammensetzungen und verfahren für die tumor-diagnose und behandlung
EP1572091A4 (de) Zusammensetzungen und verfahren für die tumordiagnose und behandlung
EP1553912A4 (de) Zusammensetzungen und verfahren f r die tumordiagnose und behandlung
EP1578380A4 (de) Zusammensetzungen und verfahren zur therapie und diagnose von prostatakrebs
EP1438062A4 (de) Verfahren und zusammensetzungen zur behandlung von hautläsionen
EP1578347A4 (de) Zusammensetzungen und verfahren für nachweis, diagnose und therapie von hämatologischen malignen erkrankungen
EP1578385A4 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von entzündlichen darmerkrankungen
EP1539251A4 (de) Zusammensetzungen und verfahren zur diagnose und therapie von medizinischen erkrankungen mit angiogenese
EP1590433A4 (de) Diagnose und prognose bei brustkrebspatienten
EP1575571A4 (de) Zusammensetzungen und verfahren zur diagnose und behandlung eines tumors
EP1756137A4 (de) Diagnostische und therapeutische verfahren und zusammensetzungen betreffend pten und brustkrebs
EP1578354A4 (de) Targets, verfahren und reagenzien für die diagnose und behandlung von schizophrenie
EP1446013A4 (de) Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs
EP1499328A4 (de) Verfahren zur behandlung von nekrotisierender enterocolitis
EP1889058A4 (de) Diagnose und behandlung von endometriose
EP1756166A4 (de) Diagnose und behandlung von prostatakrebs
EP1608967A4 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von tumoren
EP1626711A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031211

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1075674

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20051123

17Q First examination report despatched

Effective date: 20061110

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090122

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1075674

Country of ref document: HK